جست‌وجوی استاد و پژوهشگر

Robert Bateyمشاهده پروفایل

استاد

• Biological Chemistry
• Organic Chemistry
• Organoboron Chemistry
• +۷ مورد دیگر

Robert Batey is a Full Professor in the Department of Chemistry at the University of Toronto, serving as Co-Director of the Acceleration Consortium's Medicinal Chemistry Self-Driving Lab (SDL) and former Chair of the Department (2013–2023). His research focuses on organic synthesis, medicinal chemistry, and applications in drug discovery, with a particular emphasis on organoboron chemistry and protease inhibitors. He holds a B.A. from Oxford University and a Ph.D. from Imperial College London. His work bridges synthetic methods, structural analysis, and computational science, including collaborations on machine learning-driven molecule design. Key research areas include: synthetic methods using organoboron compounds, combinatorial chemistry, hetero Diels-Alder reactions, and the development of small molecules targeting ClpP proteases and ubiquitin pathways. His group has synthesized natural products like himeic acid A, kitastatin, and martinelline, as well as novel antibiotics and PROTACs. Recent publications highlight advancements in AI-driven drug design (e.g., GFlowNets for molecular generation), structure-based antibiotics development, and PROTAC complex structure prediction. Awards include the CSC Merck-Frosst Award and multiple teaching/research accolades. Awards: CSC Merck-Frosst Award, Merck Academic Development Award, Bio-Méga/Boehringer Ingelheim Young Investigator Award, and teaching excellence recognition. Advising: Active mentorship of graduate students and postdocs in organic chemistry, with a focus on independent research and problem-solving. Labs: Located in Lash Miller Building (3rd floor), including North Lab (LM 371) and South Lab (LM 370).

Shuibing Chenمشاهده پروفایل

استاد

• Stem Cell Biology
• Chemical Biology
• Regenerative Medicine
• +۴ مورد دیگر

Shuibing Chen is a Professor of Chemical Biology in Surgery at Weill Cornell Medical College, holding additional roles such as Kilts Family Professor of Surgery. She specializes in manipulating stem cell fate using chemical and biological approaches to generate functional tissues for translational research. Her work focuses on human pluripotent stem cells, including embryonic and induced pluripotent stem cells. Dr. Chen earned her PhD from The Scripps Research Institute (2006), and MS (2002) and BS (1999) degrees from Tsinghua University. Her research interests span bioactive small molecules, high-throughput screening, and chemical genetics, with therapeutic applications in cancer, cardiovascular diseases, and diabetes. Awards include the NIH Director’s New Innovator Award. Notable grants include studies on diabetes genetics, pancreatic beta cell biology, and AI-driven pancreas knowledge integration. She advises students in chemical biology and stem cell research, and collaborates with industry partners like Vesalius Therapeutics and iOrganBio INC. Dr. Chen’s lab develops scalable differentiation protocols for neurons and tissues, leveraging stem cells to model diseases such as diabetes and metabolic disorders. Her work bridges basic science with clinical applications, emphasizing regenerative medicine and drug discovery.

Anne Petitjeanمشاهده پروفایل

دانشیار

• DNA computing
• Genetics
• Supramolecular chemistry
• +۷ مورد دیگر

Dr. Anne Petitjean is an Associate Professor in the Department of Chemistry at Queen's University, affiliated with the Faculty of Arts and Science. She holds a cross-appointment as an Associate Member of the Division of Cancer Clinical Trials at the Queen's Cancer Research Institute. Education: B.Sc. in Physical Chemistry from École Normale Supérieure (Lyon, France), M.Sc. in Advanced Organic Chemistry from Université Claude Bernard (Lyon), and Ph.D. in Supramolecular Chemistry under Nobel Laureate Prof. Jean-Marie Lehn. Postdoctoral research at Caltech with Prof. Jacqueline K. Barton focused on DNA-targeting small molecules. Research focuses on supramolecular chemistry, molecular recognition, and drug delivery systems targeting non-canonical nucleic acid structures like guanine quadruplexes. Key interests include 'smart' drug delivery for cancers and infections, and molecular design for targeted therapeutics. Her work integrates organic synthesis, coordination chemistry, and dynamic systems to create bioactive molecules and advanced materials. Notable projects include metallomacrocycles for quadruplex recognition and stimuli-responsive drug delivery mechanisms.

Kenichi Yokoyamaمشاهده پروفایل

دانشیار

• Natural Products Biosynthesis
• Enzymology
• Antibiotics Research
• +۴ مورد دیگر

Kenichi Yokoyama serves as Associate Professor of Biochemistry (2019-Present), Associate Professor of Chemistry (2022-Present), and Associate Professor of Cell Biology (2022-Present) at Duke University. His primary appointment resides in the Department of Biochemistry within the Basic Science Departments, with secondary appointments in the Department of Chemistry under Trinity College of Arts & Sciences and the Department of Cell Biology. Dr. Yokoyama's research focuses on biosynthesis and mechanisms of action of naturally occurring bioactive molecules, particularly antifungals and antibiotics. His lab investigates biosynthetic enzymes and bacterial/fungal producers of bioactive metabolites to discover novel compounds with applications in research and medicine. His specific interests include free-radical mediated enzyme catalysis (metallo-enzymology), cofactor biosynthesis in humans and pathogenic bacteria, natural product biosynthesis and genome mining, and fungal cell wall biosynthesis with antifungal mode of action. His recent publications reveal a strong trend toward ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotics like dynobactins and darobactins that target Gram-negative bacterial outer membranes. His work bridges organic chemistry, biochemistry, molecular biology, and spectroscopy with emphasis on functional and mechanistic characterization of enzymes, small molecule characterization, bacterial/fungal genetics, synthetic organic chemistry, and advanced spectroscopic techniques including NMR, EPR, and fluorescence microscopy. Scientific Awards: ACS Pfizer Award in Enzyme Chemistry (2019) - Recognizing fundamental research in enzyme chemistry by scientists under forty years of age Dr. Yokoyama maintains active grant funding from multiple NIH institutes (NIAID, NIGMS), NSF, and the American Heart Association, totaling over $10 million in current funding. His grants focus on molecular mycology, chitin synthesis inhibition, cell and molecular biology training, peptide antibiotic discovery, and advanced spectroscopy equipment. His lab also mentors students through various NIH-funded training programs including the Tri-Institutional Molecular Mycology and Pathogenesis Training Program and the Cell and Molecular Biology Training Program. The Yokoyama Lab operates at the intersection of enzymology and natural products research, maintaining strong collaborations across Duke's research ecosystem with particular emphasis on translating basic enzymatic discoveries into novel therapeutics for infectious diseases.

Takayoshi Suzukiمشاهده پروفایل

استاد

• Epigenetics
• Drug Discovery
• Medicinal Chemistry
• +۵ مورد دیگر

Takayoshi Suzuki is a Professor at Osaka University's Institute of Scientific and Industrial Research (SANKEN), leading the Department of Complex Molecular Chemistry. He holds a Ph.D. in Pharmaceutical Sciences from the University of Tokyo (2005) and has held academic positions at Kyoto Prefectural University of Medicine, Nagoya City University, and Scripps Research Institute. His research integrates synthetic organic chemistry, chemical biology, and AI for drug discovery targeting epigenetic mechanisms in cancer and neurodegenerative disorders. Research Interests: Focuses on designing enzyme inhibitors (e.g., HDACs, KDMs), developing PROTACs, and creating bioactive molecules for precision medicine. Key areas include cancer-selective therapeutics, epigenetic reprogramming, and chemical probe development. Awards & Honors: Ewha Global Fellow (2024) MEXT Commendation for Science and Technology (2011) Pharmaceutical Society of Japan Young Chemist Award (2009) Lab & Advising: Directs a team of 25+ students (PhD, Master's, Bachelor's) and staff. Research emphasizes interdisciplinary collaboration, with recent student accolades including Poster Awards at international conferences.

Caetano Antunesمشاهده پروفایل

استادیار

• Microbiology
• Host-Microbe Interactions
• Gut Microbiome
• +۳ مورد دیگر

Caetano Antunes is an Assistant Professor in the Department of Molecular Biosciences at the University of Kansas, where he joined in January 2023 after transitioning from Fundação Oswaldo Cruz in Rio de Janeiro, Brazil. His research program focuses on host-microbe interactions with particular emphasis on small molecules in the gut metabolome and their effects on bacterial pathogen behavior. Dr. Antunes earned his B.Sc. and M.Sc. in Microbiology from Universidade Federal do Rio de Janeiro (2000, 2002), completed his Ph.D. at the University of Iowa (2007), and conducted post-doctoral research at the University of British Columbia (2008-2012). His work bridges microbiology, metabolomics, and molecular biology to understand how microbial metabolites influence pathogen virulence and host responses. His recent publications reveal a consistent focus on gut microbiome-derived small molecules and their regulatory effects on bacterial pathogens like Salmonella and Vibrio cholerae. His research spans from basic molecular mechanisms to potential therapeutic applications targeting pathogen virulence without directly killing bacteria, representing a promising antivirulence approach to combat antibiotic resistance. Dr. Antunes teaches courses including Introduction to Honors Research, Immunology Laboratory, Rigor and Reproducibility in Research, and Advanced Molecular Genetics, demonstrating his commitment to training the next generation of scientists in both foundational and advanced molecular techniques.

Mark Baillieمشاهده پروفایل

استادیار

• Chemistry Education Research
• STEM Education
• Institutional Change Research
• +۳ مورد دیگر

Dr. Mark Baillie is an Assistant Professor in the Department of Chemistry at the University of Arkansas at Little Rock. He also serves as Director of the STRIVE Program and the Mobile Institute on Scientific Teaching (MoSI) Workshop. His research focuses on Chemistry Education Research and Institutional Change Research, exploring how faculty training, teaching strategies, and student backgrounds impact STEM success. He holds a PhD in Organic/Medicinal Chemistry from Emory University and a BS from Bucknell University. Education highlights include a Post-Doctoral Fellowship in Chemical Biology at EPFL (Switzerland), an Emory University NSF Fellowship, and a Six Sigma Green Belt from General Electric. His work bridges educational innovation with organic chemistry expertise, addressing barriers to equitable STEM participation through programs like Learning Assistant initiatives and evidence-based teaching workshops. Research trends show a transition from medicinal chemistry (e.g., Enigmol anti-cancer agents) to STEM education analytics, using machine learning for classroom monitoring. Awards include multiple Student Faculty Appreciation Awards and recognition as a Rising Star in STEM education. His Baillie Research Group collaborates on institutional reforms and active learning frameworks, emphasizing student mindset and belongingness in STEM retention. Key Awards: Student Faculty Appreciation Award 2023 NSF Graduate Fellowship (2007–2008) Outstanding Teaching Assistant Award (2006) Advising/Grants: Leads workshops and programs without explicit grant mentions in provided texts. Labs/Teams: Directs the Baillie Research Group, focusing on education research and institutional change.

J. D. Tovarمشاهده پروفایل

استاد

• Organic Chemistry
• Materials Chemistry
• π-Conjugated Systems
• +۷ مورد دیگر

J. D. Tovar is a Professor in the Department of Chemistry at the Krieger School of Arts and Sciences, Johns Hopkins University, where he has been a faculty member since 2005. His research group focuses on the design, synthesis, and characterization of organic materials with extended π-electron conjugation for applications in flexible electronics and biomedical devices. His research interests include: Organic and materials chemistry of π-conjugated systems Boron-based aromatics, particularly borepins and their fused derivatives Methano[10]annulene-based electronic materials Photochromic polymers and molecular switches Self-assembling bioelectronic materials using peptide-π conjugates Energy transport in organic electronic materials The recent publications from Prof. Tovar's group emphasize the development of air- and moisture-stable organoboron materials, fine-tuning of aromaticity in fused borepin systems, and the design of functional peptide-based nanomaterials. These works span synthetic organic chemistry, physical characterization, and materials engineering, reflecting a multidisciplinary approach to organic electronics and bio-nanomaterials. The research demonstrates a strong trend toward molecular design for controlling electronic, optical, and self-assembly properties in functional materials. Prof. Tovar has successfully advised numerous Ph.D. and M.A. students, many of whom have gone on to postdoctoral positions at institutions like Harvard, NIH, and NIST, or careers in industry at companies such as Solid Biosciences, Church & Dwight, and Kite Pharma. His group has received consistent funding to support graduate students, postdocs, and research activities in the laboratory. He has mentored a diverse cohort including REU students from various universities, indicating active participation in undergraduate research training. The Tovar Research Group operates a well-equipped laboratory focused on organic synthesis, optical and electrochemical characterization, and materials testing. The lab fosters a collaborative environment where students gain expertise in aromatic and polymer chemistry, peptide synthesis, and advanced analytical techniques. Current projects involve cycloparaphenylenes, peptide-π hydrogels, and bioelectronic heterostructures, suggesting ongoing innovation in both fundamental and applied directions.

Damian Kułagaمشاهده پروفایل

استادیار

• Medicinal Chemistry
• Organic Chemistry
• Computational Chemistry
• +۴ مورد دیگر

Dr. Eng. Damian Kułaga is a Research and Teaching Assistant Professor at the Department of Organic Chemistry and Technology (C-2) , Faculty of Chemical Engineering and Technology, Tadeusz Kościuszko Cracow University of Technology. He obtained his M.Sc. in Light Organic Technology (2015) and Ph.D. in Chemical Engineering (2023) from the same institution, with postgraduate pedagogical studies completed in 2020. Education M.Sc. in Light Organic Technology, Cracow University of Technology (2015) Ph.D. in Chemical Engineering, Cracow University of Technology (2023) Postgraduate Pedagogical Studies, Cracow University of Technology (2020) Kułaga's research spans Medicinal Chemistry , Organic Synthesis , and Computational Drug Design , focusing on: Designing bioactive compounds for CNS disorders (depression, schizophrenia) and oncology (TNBC, CRC) Lead optimization for improved pharmacological parameters (ADME-T) Docking and molecular dynamics for structure-based drug design Green chemistry methods (microwave/sound-assisted solvent-free reactions) Synthesis of heterocycles and steroid bioconjugates His work has produced 15+ publications (2016–2025) on topics including: Anticancer triazine derivatives for colorectal cancer Dual-target ligands for Alzheimer’s and CNS diseases Ultrasound/microwave-assisted drug synthesis protocols 5-HT7 receptor agonists/antagonists for psychiatric and oncological applications Scientific Awards : GOLD MEDAL ARCA 2017 (Trazodone synthesis method) BRONZE AWARD KIWIE2017 (Aripiprazole synthesis) GOLD MEDAL IWIS2018 (solvent-free active substance synthesis) Multiple international medals (SILVER, HONORABLE MENTION) for CNS and oncology drug innovations First place poster award at X Medical Chemistry Symposium (2021) Grants & Projects : NCBiR LIDER grants for 5-HT7 receptor ligands in TNBC (2022–2025) and CNS ligands (2016–2019) Subwencja N+B grant for indolyl aminotriazines (2021–) FNP/Proof of Concept grant for DK-AT390HCI small-molecule anticancer agent (2024–2025) International Collaborations : Research stays at Sapienza Universita di Roma (Italy), Institute of Pharmacology PAN (Poland), and Experimental & Innovative Medicine Center UJ-UR (Poland)

Petra Janningمشاهده پروفایل

پژوهشگر

• Chemical Biology
• Mass Spectrometry
• Proteomics
• +۳ مورد دیگر

Dr. Petra Janning serves as Project Group Leader in the Department of Chemical Biology at the Max Planck Institute of Molecular Physiology (Dortmund), directing the Mass Spectrometry Group which operates three core facilities: Low-Resolution Mass Spectrometry, High-Resolution Mass Spectrometry, and Proteomics services. Her research spans Chemical Biology and advanced mass spectrometry techniques with primary focus areas: Structural elucidation of low molecular weight compounds Proteome-wide protein identification and quantification Target engagement studies of bioactive compounds Thermal Proteome Profiling for drug target identification Analysis of protein-protein interactions and post-translational modifications Recent publication trends demonstrate specialization in thermal profiling methodologies for small molecule target engagement, particularly through Thermal Proteome Profiling (TPP) applications in drug discovery. The Mass Spectrometry Group provides critical infrastructure for synthesis validation, intact protein analysis, and complex proteomics workflows including SILAC, TMT-label, and label-free quantification approaches. Her group maintains comprehensive service capabilities including nano-HPLC/ESI-MS/MS instrumentation for target identification via pulldown assays, cellular thermal shift experiments, and hydrogen-deuterium exchange mass spectrometry.

Andreas Deckenمشاهده پروفایل

دانشیار

• Inorganic Chemistry
• X-ray Crystallography
• Organic Materials
• +۲ مورد دیگر

Andreas Decken is an Associate Professor in the Department of Chemistry at the University of New Brunswick. His laboratory specializes in X-ray crystallography for molecular structure determination of organic and inorganic compounds, with research spanning anti-cancer drug candidates and materials for organic batteries. Key research areas: Molecular packing and material properties prediction Structural analysis of small organic/inorganic molecules Functional materials development His recent publications focus on synthetic organic chemistry, catalysis, and materials design, with significant contributions to heterocyclic chemistry and coordination complexes. He maintains office Toole Hall 131 at the Fredericton campus and can be reached at adecken@unb.ca or 1-506-261-2923.

Yan-Yeung Lukمشاهده پروفایل

دانشیار

• Bioorganic Chemistry
• Chemical Biology
• Microbial Signaling
• +۴ مورد دیگر

Yan-Yeung Luk is an Associate Professor in the Department of Chemistry at Syracuse University. His research focuses on organic synthesis of bioactive molecules to control microbial lifestyles, bacterial signaling pathways, and developing label-free bioassays for ligand-receptor interactions. He holds a Ph.D. in Bioorganic Chemistry from the University of Chicago (2001). Education: Ph.D., Bioorganic Chemistry, University of Chicago (2001) M.A., Chemistry, University of Chicago (1996) B.A., Chemistry, Polytechnic University (1994) Research interests include: - Synthesis of small molecules to combat drug tolerance and resistance in bacteria - Engineering bacterial motility-enabled binding (BMED) assays for selective ligand detection - Understanding bacterial surface signaling and its role in virulence and biofilm formation Recent publications focus on ligand-based modulation of bacterial behavior, antibiotic mechanisms affecting biofilms, and novel antivirulence strategies. His work has implications for combating multidrug-resistant pathogens. Grants include leadership in NSF-funded undergraduate research programs and NIH grants exploring bacterial natural product genes. He serves on Syracuse University's Financial Conflict of Interest Committee and reviews for the NIH/NIAID. Teaching responsibilities include medicinal chemistry, organic spectroscopy, and research methodologies at both undergraduate and graduate levels.

A. Ganesanمشاهده پروفایل

استاد

• Chemical Biology
• Medicinal Chemistry
• Organic Synthesis
• +۳ مورد دیگر

Professor A. Ganesan is Chair of Chemical Biology at the University of East Anglia's School of Chemistry, Pharmacy and Pharmacology, where he serves as Director of Postgraduate Research and Head of the Healthy Ageing research theme. He co-founded Karus Therapeutics and chairs the EU COST Action 'Epigenetic Chemical Biology', while holding key roles in IUPAC and the Royal Society of Chemistry. Education BSc (Hons) in Chemistry, National University of Singapore (1986) PhD in Synthetic Methodology and Total Synthesis, University of California-Berkeley (1992) Postdoctoral Fellowship, Harvard University (1992-1993) His research focuses on chemical biology and medicinal chemistry, specializing in biologically active natural products and epigenetic mechanisms. Current work emphasizes drug discovery for cancer and age-related diseases, particularly through HDAC and LSD1 inhibition, with strong translation potential via industry partnerships like Karus Therapeutics. His group combines synthetic organic chemistry with computational approaches to develop novel therapeutics targeting epigenetic pathways. Recent publications (2023-2025) show a shift toward computational drug design for epigenetic targets, especially HDAC6 inhibitors for cancer therapy, while earlier work centered on natural product synthesis and calcium signaling mechanisms. This evolution reflects growing integration of AI-driven docking studies with traditional synthetic approaches. Research Leadership Director of Postgraduate Research at UEA School of Pharmacy Head of Healthy Ageing Research Theme Chair of EU COST Action CM1406 'Epigenetic Chemical Biology' Member of IUPAC Subcommittee for Medicinal Chemistry He actively supervises PhD students with current projects on marine-derived antibiotics, plant bioactives from Malaysian/Middle Eastern botanicals, and fungal metabolites. Major grants include Cancer Research UK (£91k, 2007-2011) for histone methylation inhibitors and BBSRC funding (£351k, 2009-2012) for NAADP receptor antagonists, plus ongoing Saudi/Kuwaiti-funded initiatives in natural product discovery.

Slava Zieglerمشاهده پروفایل

پژوهشگر

• Chemical Biology
• Bioactive Small Molecules
• Target Identification
• +۳ مورد دیگر

Dr. Slava Ziegler is a Project Group Leader at the Department of Chemical Biology , Max Planck Institute of Molecular Physiology in Dortmund, Germany. His research focuses on identifying bioactive small molecules and elucidating their molecular targets and mechanisms of action through chemical proteomics, biochemical, biophysical and genetic approaches. Academic Appointments : Project Group Leader, Chemical Biology (2016-present) Education : Diploma in Biochemistry (Ruhr University Bochum), PhD in Biochemistry (MPI & Ruhr University), Postdoc at University Hospital Düsseldorf Research Interests center on: Phenotypic screening using Cell Painting assays Target identification for bioactive compounds Proteome and lipidome profiling Developmental signaling pathway inhibition Glucose transporter and glutaminase targeting Chemical genetics in cancer metabolism Notable Contributions include developing high-throughput screening workflows, discovering novel Hedgehog and TRPC inhibitors, and creating chemical probes for: Dihydroorotate Dehydrogenase RHOGDI PI4KIIIß IDO1 TAF1 Bromodomain 5-Lipoxygenase Collaborations with researchers across Europe and Japan have yielded significant insights into: Autophagy regulation Lysosomal membrane repair Microtubule destabilization Proteasome inhibition Neutrophil extracellular traps Embryonic stem cell reprogramming Contact : slava.ziegler@mpi-dortmund.mpg.de | +49 231 133-2424

Kasper Harpsøeمشاهده پروفایل

پژوهشگر

• Computational Chemistry
• Molecular Modeling
• GPCR Research
• +۶ مورد دیگر

Kasper Harpsøe is a Research Consultant and Data and Computing Facility Manager at the Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen. He has extensive expertise in computational medicinal chemistry with over 15 years of experience in molecular modeling techniques, particularly focused on G Protein-Coupled Receptors (GPCRs). Harpsøe earned his Ph.D. in Computational Chemistry from The Danish University of Pharmaceutical Sciences in 2006 with research on "Computational Studies on the Allosteric Modulation of AMPA Receptors." He holds a Master of Science in Pharmacy (Cand. Pharm.) from The Royal Danish School of Pharmacy completed in 2001. His international experience includes a three-month traineeship at Schrödinger Inc. in New York and research collaboration with the Carlson group at the University of Michigan. His research expertise spans structure-based design of peptide and small molecule ligands, binding site identification, docking and binding pose evaluation, protein-ligand interactions, conformational analysis, QSAR, sequence analysis, homology modeling, molecular dynamics, and quantum chemistry calculations. Harpsøe has made significant contributions to understanding GPCR structure-function relationships, ligand recognition mechanisms, and G protein coupling specificity. Analysis of his publication record reveals a consistent focus on GPCR molecular pharmacology, with particular emphasis on serotonin receptors, orphan receptors like GPR139, and GABA receptors. His work integrates computational approaches with experimental validation to identify molecular determinants of receptor selectivity and to design novel ligands for therapeutic applications. The research bridges structural biology, molecular modeling, and medicinal chemistry in the context of drug discovery. Harpsøe currently manages the department's Data and Computing Facility, overseeing a GPU Linux cluster and providing computational support for research groups. Previously, from 2014 to 2021, he served as project manager for computational drug design activities within the Gloriam Group, working on multidisciplinary drug discovery projects in collaboration with medicinal chemists, molecular pharmacologists, structural biologists, and data scientists from both academia and industry.